99 related articles for article (PubMed ID: 19846023)
1. Infliximab for the treatment of ulcerative colitis.
Hyde C; Bryan S; Juarez-Garcia A; Andronis L; Fry-Smith A
Health Technol Assess; 2009 Oct; 13 Suppl 3():7-11. PubMed ID: 19846023
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for the treatment of acute exacerbations of ulcerative colitis.
Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D
Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
4. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab for the treatment of severe persistent allergic asthma.
Jones J; Shepherd J; Hartwell D; Harris P; Cooper K; Takeda A; Davidson P
Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
Punekar YS; Hawkins N
Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
[TBL] [Abstract][Full Text] [Related]
8. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Jones ML; Holmes M
Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
11. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
13. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
16. The use of paclitaxel in the management of early stage breast cancer.
Griffin S; Dunn G; Palmer S; Macfarlane K; Brent S; Dyker A; Erhorn S; Humphries C; White S; Horsley W; Ferrie L; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():15-22. PubMed ID: 19567209
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib for the treatment of multiple myeloma patients.
Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis.
Park KT; Tsai R; Perez F; Cipriano LE; Bass D; Garber AM
Ann Surg; 2012 Jul; 256(1):117-24. PubMed ID: 22270693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]